GlassScriptPhysician profile
Kayla J Campbell
NPI 1306253166
$15,641.28
in general payments reported to CMS, 2019-2025
28 companies · $6,606 in 2025
The $6,606 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,041 · 2020: $326 · 2021: $2,631 · 2022: $1,740 · 2023: $1,706 · 2024: $1,592 · 2025: $6,606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,100 · Consulting Fee: $4,725 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,099.68 |
| Consulting Fee | $4,725.00 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,823.49 | 2024-2025 | |
| Bausch & Lomb Americas INC. | $2,342.61 | 2022-2025 | Infuse, Xiidra, Miebo |
| Eyevance Pharmaceuticals LLC | $1,755.41 | 2019-2021 | |
| Alcon Vision LLC | $1,490.55 | 2019-2025 | Total30, Dailies Total1, Clareon |
| Sun Pharmaceutical Industries INC. | $1,437.83 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $631.70 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $560.72 | 2019-2025 | Acuvue |
| Abbvie INC. | $313.02 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Dompe US, INC. | $297.41 | 2021-2025 | Oxervate |
| Lkc Technologies, INC. | $241.27 | 2023-2024 | |
| Tarsus Pharmaceuticals, INC. | $224.89 | 2024-2025 | Xdemvy |
| Topcon Healthcare, INC. | $207.71 | 2025 | |
| Novartis Pharmaceuticals Corporation | $183.62 | 2019-2023 | |
| Oyster Point Pharma, INC. | $177.87 | 2022-2025 | Tyrvaya, Ryzumvi |
| Allergan, INC. | $175.27 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $144.71 | 2025 | Myday Contact Lens |
| Genmab U.S., INC. | $125.00 | 2025 | Tivdak |
| Optos, INC. | $108.10 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.08 | 2022 | |
| Seagen INC. | $79.00 | 2023 | |
| Shire North American Group INC | $67.48 | 2019 | |
| Kala Pharmaceuticals, INC. | $29.15 | 2021-2022 | |
| Thea Pharma INC. | $23.05 | 2025 | Iyuzeh |
| Merck Sharp & Dohme LLC | $21.95 | 2025 | Keytruda |
| Harrow Eye, LLC | $21.85 | 2024 | Vevye |
| Aerie Pharmaceuticals, INC. | $20.90 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $16.98 | 2019 | |
| Biotissue Holdings INC. | $15.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.